Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
NCT ID | NCT03401788 |
Title | A Phase 2 Study of Belzutifan (PT2977, MK-6482) for the Treatment of Von Hippel Lindau (VHL) Disease-Associated Renal Cell Carcinoma (RCC) (MK-6482-004) |
Recruitment | Active, not recruiting |
Gender | both |
Phase | Phase II |
Variant Requirements | Yes |
Sponsors | Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) |
Indications | |
Therapies | |
Age Groups: | senior | adult |
Covered Countries | USA | GBR | FRA | DNK |
Facility | Status | City | State | Zip | Country | Details |
---|---|---|---|---|---|---|
National Institutes of Health Clinical Center | Bethesda | Maryland | 20892 | United States | Details | |
Massachusetts General Hospital | Boston | Massachusetts | 02114 | United States | Details | |
University of Michigan | Ann Arbor | Michigan | 48109 | United States | Details | |
University of Pennsylvania Medical Center | Philadelphia | Pennsylvania | 19104 | United States | Details | |
University of Pittsburgh Medical Center | Pittsburgh | Pennsylvania | 15232 | United States | Details | |
Vanderbilt Medical Center | Nashville | Tennessee | 37232 | United States | Details | |
MD Anderson Cancer Center | Houston | Texas | 77030 | United States | Details | |
Huntsman Cancer Institute | Salt Lake City | Utah | 84112 | United States | Details | |
Aarhus University Hospital | Aarhus | Denmark | Details | |||
Hospital Georges Pompidou | Paris | France | Details | |||
Cambridge University Hospital | Cambridge | United Kingdom | Details |